Investor Relations

IR Home

Stock Chart
VNDA (Common)
ExchangeNASDAQ (US Dollar)
Price$13.58
Change (%) Stock is Down 0.27 (1.95%)
Volume904,063
Data as of 04/17/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile

Vanda is developing important new medicines to improve the lives of patients. We use new technologies, including genetics and genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. We are working to advance the science of developing new medicines and to use novel approaches to deliver these new medicines to patients... More >>

April 2014?
Calendar Help
This calendar contains six months of past and future company related information, which may include press releases, SEC filings, calendar events and more. Dates containing information are indicated by a colored background. You may hover your mouse over a date that contains an event to reveal the event or events taking place on that day including a link to additional information. This calendar requires JavaScript to be installed and activated on your browser.
Calendar Icon Legend:
Analyst Meeting
Conference
Conference Presentation
Corporate Conference Call
Custom Events
Earnings Conference Call
Earnings Release
Financial Reports
Mergers & Acquisition Announcement
Guidance Announcement
Other Corporate
Sales Call/Presentation
Sales Release
Shareholders Meeting
News Release
SEC Filings
Presentations
52 Week High
Today
SunMonTueWedThuFriSat
-2-112345
67
04/07/14
DEFA14A
Formats:  Excel HTML Adobe PDF Word
DEF 14A
Formats:  Excel HTML Adobe PDF Word
8910
04/10/14
8-K
Formats:  Excel HTML Adobe PDF Word
1112
13141516171819
20212223242526
27282930515253

Primary IR Contact

For members of the press or investor community who wish to obtain more information about Vanda, please contact
Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals, Inc.
(202) 734-3428

Recent News
04/09/14
Vanda Pharmaceuticals Announces Availability of HETLIOZ™ (tasimelteon) for Non-24-Hour Sleep-Wake Disorder (Non-24)
02/28/14
Blind Adventurer, Erik Weihenmayer, Launches National Campaign to Raise Awareness of Non-24-Hour Sleep-Wake Disorder
02/13/14
Vanda Pharmaceuticals Reports Fourth Quarter 2013 and Full Year 2013 Results
More >>
Upcoming Events
There are currently no events scheduled.
More >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
  
Home | About Vanda | Product Pipeline | 24 | Partnering | Investor Relations | News | Careers | Contact Us
Copyright © 2005-2007 Vanda Pharmaceuticals | Terms & Conditions | Privacy Policy